Facilitating Antibody Functional Evaluation with a Fc Receptor Binding Kit Solution

Can't see this email? View it online

	Drug Discovery
	The latest drug discovery news from News Medical

Facilitating Antibody Functional Evaluation with a Fc Receptor Binding Kit Solution！

ACRO have developed a Human Fc gamma RI / CD64 Binding Kit (TR-FRET) (Cat. No. FRT-03), which is designed to facilitate the ADCC and ADCP functional performance evaluation of antibody drug candidates, and high-throughput screening of anti-human CD64-specific antibodies within 0.5-1 hours. A free sample (100 tests) is available, so don’t miss your chance!

Request your free sample now

Do More with Your Data

There’s no limit to what you can achieve with a reimagined digital strategy. LabVantage Solutions helps with a modern, expanding informatics platform and professional services that deliver powerful, problem-solving solutions to your greatest data challenges.

Learn how LabVantage helps organizations achieve digital transformations to gain a competitive advantage.

Download the white paper

New technology streamlines drug discovery using single-molecule tracking

New drug discovery is a critical step for improving patients' lives. First, researchers must identify molecules in the body's cells that help drive disease, as these are potential targets for new drugs. The next step is to screen candidate drugs that can hit those targets.

Recruitment underway for a clinical trial testing new vaccine against respiratory viruses

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.

	Innovative Biocatalysis Method Promises Faster, Greener Drug Manufacturing Researchers have found a new way to use biocatalysis to improve the production of critical raw materials required for essential drugs, making the process quicker, more efficient, and environmentally friendly.

	Innovative Drug-Design Strategies to Overcome Antibacterial Resistance Antibacterial resistance poses a global health threat, necessitating innovative drug design and delivery strategies to combat multi-drug-resistant infections.

	Key FDA Decisions Made in 2024 Regulating drug discovery and pharmaceutical manufacturing, the FDA ensures the safety and effectiveness of innovative therapies and medical devices.

	Targeted degradation of Pin1 shows promise for pancreatic cancer treatment In drug discovery, targeted protein degradation is a method that selectively eliminates disease-causing proteins.

	Study uncovers why white button mushrooms may help prevent prostate cancer progression Researchers at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, ranked among the nation's top 5 cancer centers by U.S.

	Rutgers study sheds light on how bedaquiline fights drug-resistant tuberculosis Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development strategies.

	Combination therapy shows promising results in treating stage 3 melanoma Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical trial led by the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute (NCI).

	Adipo Therapeutics shares results of studies on potential obesity treatment Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and related metabolic disorders, presented data from two studies at the annual meeting of The Obesity Society in San Antonio.

	New therapeutic target overcomes ovarian cancer immunotherapy resistance Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance.